Abstract
Summary
Treatment with alendronate (Fosamax®) has been shown to significantly reduce the risk of fragility fractures. Cost-effectiveness of treatment was assessed in nine European countries in a Markov model and was generally found to be cost effective in women with a previous spine fracture.
Introduction
Treatment with alendronate (Fosamax®) reduces the risk of osteoporotic fractures at the spine, hip and wrist in women with and without prevalent vertebral fracture. Cost-effectiveness estimates in one country may not be applicable elsewhere due to differences in fracture risks, costs and drug prices. The aim of this study was to assess the cost-effectiveness of treating postmenopausal women with alendronate in nine European countries, comprising Belgium, Denmark, France, Germany, Italy, Norway, Spain, Sweden, and the UK.
Methods
A Markov model was populated with data for the nine European populations. Effect of treatment was taken from the Fracture Intervention Trial, which recruited women with low BMD alone or with a prior vertebral fracture.
Results
The cost per QALY gained of treating postmenopausal women with prior vertebral fractures ranged in the base case from “cost saving” in the Scandinavian countries to €15,000 in Italy. Corresponding estimates for women without prior vertebral fractures ranged from “cost saving” to €40,000.
Conclusions
In relation to thresholds generally used, the analysis suggests that alendronate is very cost effective in the treatment of women with previous vertebral fracture, and in women without previous vertebral fracture, cost-effectiveness depends on the country setting, discount rates, and chosen monetary thresholds.
Similar content being viewed by others
References
Melton LJ 3rd (1993) Hip fractures: a worldwide problem today and tomorrow. Bone 14(Suppl 1):S1–S8
Black DM, FIT Research Group et al (2000) Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. J Clin Endocrinol Metab 85(11):4118–4124
Black DM, Fracture Intervention Trial Research Group et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348(9041):1535–1541
Cummings SR et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. Jama 280(24):2077–2082
Johnell O et al (2003) Cost-effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 21(5):305–314
Borgström F et al (2003) Cost-effectiveness of alendronate for the treatment of postmenopausal women in the UK. submitted
Borgström F et al (2003) Cost-Effectiveness of alnedronate in the treatment of male osteoporosis. Bone. accepted
Jonsson L, Borgstrom F, Zethraeus N (2003) [Cost-effectiveness of alendronate treatment of osteoporosis in Denmark. An economic evaluation based on the fracture intervention trial]. Ugeskr Laeger 165(43):4112–4116
Rosner AJ et al (1998) Cost-effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis. Pharmacoeconomics 14(5):559–573
Christensen PM, Brixen K, Kristiansen IS (2003) Danish osteoporosis outcome model (DOOM)
Borgstrom F, Zethraeus N (2003) [Economic assessment based on a clinical study of risedronate. Fracture prevention in elderly women with osteoporosis is cost-effective]. Lakartidningen 100(1–2):36-40
Stevenson M, Davis S (2006) Analyses of the cost-effectiveness of pooled alendronate and risedronate, compared with strontium ranelate, raloxifene, etidronate and teriparatide. [cited 2007-01-03]; Available from: http://www.nice.org.uk/page.aspx?o=370643
Stock JL et al (1997) Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med 103(4):291–297
Greenspan SL et al (2002) Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 137(11):875–883
Tonino RP, Phase III Osteoporosis Treatment Study Group et al (2000) Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab 85(9):3109–3115
Bone HG et al (2004) Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350(12):1189–1199
Borgstrom F et al (2006) An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: Based on the results of the SOTI and TROPOS trials. Osteoporos Int 17(12):1781–1793
Federaal Ministerie van Sociale Zaken, Volksgezondheid en Leefmilieu. (Belgium)
Vestergaard P, Rejnmark L, Mosekilde L (2005) Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark. Osteoporos Int 16(2):134–141
Elffors I et al (1994) The variable incidence of hip fracture in southern Europe: the MEDOS Study. Osteoporos Int 4(5):253–263
Lofthus CM et al (2001) Epidemiology of hip fractures in Oslo, Norway. Bone 29(5):413–418
Kanis JA et al (2000) Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int 11(8):669–674
Singer BR et al (1998) Epidemiology of fractures in 15,000 adults: the influence of age and gender. J Bone Joint Surg Br 80(2):243–248
Brecht JG et al (2003) Pharmacoeconomic analysis of osteoporosis treatment with risedronate. Int J Clin Pharmacol Res 23(4):93–105
Kanis JA et al (2000) Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden. Osteoporos Int 11(2):120–127
Kanis JA et al (2004) Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos Int 15(11):862–871
Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Br Med J 312(7041):1254–1259
Looker AC et al (1998) Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 8(5):468–489
Klotzbuecher CM et al (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15(4):721–739
Kanis JA et al (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35(2):375–382
Felsenberg D et al (2002) Incidence of vertebral fracture in Europe: results from the European prospective osteoporosis study (EPOS). J Bone Miner Res 17(4):716–724
Report on osteoporosis in the European community-action for prevention. 1998, European Commission-Employment & Social Affairs
Zethraeus N (1998) Willingness to pay for hormone replacement therapy. Health Econ 7(1):31–38
Life tables, years 1999–2001. Institut National d’Édutes démographiques. 2004
Johannesson M (1996) Theory and methods of economic evaluation of health care. Dev Health Econ Public Policy 4:1–245
Tengs TO, Wallace A (2000) One thousand health-related quality-of-life estimates. Med Care 38(6):583–637
Statistics Norway http://www.ssb.no/). 2004
Christensen PM et al (2005) Cost-effectiveness of alendronate in the prevention of osteoporotic fractures in Danish women. Basic Clin Pharmacol Toxicol 96(5):387–396
Statistics Sweden. Sweden´s Statistical Databases. http://www.scb.se/eng/databaser/ssd.asp
Interim Life Tables. 2002 [cited http://www.gad.gov.uk/policy_and_stats/life_tables.htm
Oden A et al (1998) Lifetime risk of hip fractures is underestimated. Osteoporos Int 8(6):599–603
Kanis JA et al (2003) The components of excess mortality after hip fracture. Bone 32(5):468–473
Parker MJ, Anand JK (1991) What is the true mortality of hip fractures? Public Health 105(6):443–446
Kanis J et al (2002) Excess mortality after vertebral fracture. WHO Collabortaing centre for metabolic bone diseases: Sheffield, UK
ISPOR, Pharmacoeconomic guidelines. 2005, http://www.ispor.org/PEguidelines/index.asp
TIPOS DE INTERÉS, BANCO DE ESPAÑA/ESTADÍSTICAS COMPLEMENTARIAS. http://www.bde.es/, 2005
Zethraeus N et al (1997) The cost of a hip fracture. Estimates for 1,709 patients in Sweden. Acta Orthop Scand 68(1):13–17
Zethraeus N et al (2002) Costs and quality of life associated with osteoporosis related fractures-results from a swedish survey. Working Paper Series in Economics and Finance, 512
OECD Health Data 2003-A comparative analysis of 30 countries. 2003 [cited; Available from: www.oecd.org/health/healthdata
World development indicators-relative prices and exchange rates. 2004 [cited 2004; Available from: http://siteresources.worldbank.org/ICPINT/Resources/Table5_7.pdf
Kanis JA et al (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12(5):417–427
Zethraeus N Strom O, Borgstrom F (2006) What is the risk of institutionalization after hip fracture? Poster at ECCEO, Vienna
Jönsson B et al (1996) Cost-effectiveness of fracture prevention in established osteoporosis. Scand J Rheumatol Suppl 103:30–38
Kind P et al (1998) Variations in population health status: results from a United Kingdom national questionnaire survey. Br Med J 316(7133):736–741
Lundberg L et al (1999) Health state utilities in a general population in relation to age, gender and socioeconomic factors. Eur J Public Health 9(3):211–217
Kanis JA et al (2004) The risk and burden of vertebral fractures in Sweden. Osteoporos Int 15(1):20–26
Brazier JE, Green C, Kanis JA (2002) A systematic review of health state utility values for osteoporosis-related conditions. Osteoporos Int 13(10):768–776
Raftery J (2001) NICE: faster access to modern treatments? Analysis of guidance on health technologies. Br Med J 323(7324):1300–1303
Översyn av samhällsekonomiska metoder och kalkylvärden på transportområdet-ASEK Review of cost benefit calculation. Methods and valuations in the transport sector. SIKA Rapport, 2002. 4
Kanis JA, Jönsson B (2002) Economic evaluation of interventions for osteoporosis. Osteoporos Int 13(10):765–767
Macroeconomics and Health: investing in health for economic development. Report of the Commission on Macroeconomics and Health, W.C.o.M.a. Health, Editor. 2001:Geneva
Hart WM et al (2002) Análisis farmacoeconómico del tratamiento de la osteoporosis postmenopáusica con risedronato o alendronato. REEMO 11(3):97–104
Autier P, Belgian Hip Fracture Study Group et al (2000) Costs induced by hip fractures: a prospective controlled study in Belgium. Osteoporos Int 11(5):373–380
Ankjaer-Jensen A, Johnell O (1996) Prevention of osteoporosis: cost-effectiveness of different pharmaceutical treatments. Osteoporos Int 6(4):265–275
Visentin P, Ciravegna R, Fabris F (1997) Estimating the cost per avoided hip fracture by osteoporosis treatment in Italy. Maturitas 26(3):185–192
Andersen L et al (1995) Cost-effectiveness of alendronate for the prevention of osteoporotic fractures in Norwegian women. Statens Institutt for Folkhelse: Oslo
Dolan P, Torgerson DJ (1998) The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int 8(6):611–617
Kanis JA (2002) Epidemiology and costs of fractures in the UK: Background document for male osteoporosis model. Personal communication
Zethraeus N et al (2002) Costs and quality of life associated with osteoporosis related fractures-results from a Swedish survey. Working paper series in economics and finance, 512. Stockholm: Stockholm School of Economics
Puffer S et al (2004) Health care costs of women with symptomatic vertebral fractures. Bone 35(2):383–386
Local Government in Denmark. http://www.kl.dk/240830
1. Stockholms stads budgetavräkning. Stadsledningskontorets redovisningsstab 2003 [cited]
Netten A, Rees T, Harrison G (2002) Unit costs of health and social care. Personal social services research unit: University of Kent. p. http://www.ukc.ac.uk/PSSRU/
System BSS Belgian Social Security System. [cited 2005-07-02]; Available from: http://www.riziv.be/insurer/fr/rate/pdf/2004/doctors/raad-20041001-fr.pdf
The danish ministry of health. Takstsystem 2001, 2000. ISBN 1395–2528
AMeli, L’Assurance Maladie en Ligne 2004 [cited; Available from: http://www.ameli.fr
EBM 2000 plus. 2004, Kassenärztliche Vereinigung Bayern
Medi 3 (internet reference,Norwegian private healthcare). 2005 [cited; Available from: http://www.medi3.no
Honorato J et al (2004) Pharmacoeconomic analysis of bemiparin and enoxaparin as prophylaxis for venous thromboembolism in total knee replacement surgery. Pharmacoeconomics 22(13):885–894
Curtis L, Netten A (2004) Unit costs of health and social care. Personal social services research unit: University of Kent. p. http://www.ukc.ac.uk/PSSRU/
Osteoporosis in the European community: A call to action: an audit of policy developments since 1998, in international osteoporosis foundation. 2001
Priser för södra sjukvårdsregionen-Vårdtjänster per klinik. 2003 Universitetssjukhuset i Lund
Stevenson M, Jones ML, Nigris Ed. Assessment report: The clinical effectiveness and cost effectiveness of prevention and treatment of osteoporosis, http://www.nice.org. 2004 [cited
centre Belge d’Information Pharmacothérapeutique, the Belgian Pharmacotherapeutic Information Centre. 2005 [cited; Available from: http://www.cbip.be/GGR/MPG/MPG_NH.cfm#MP_2541
Lægemiddelkataloget (Denmark). 2004 [cited; Available from: http://www.lmk.dk
Vidal-pro (L’information de référence sur le médicament). 2004 [cited; Available from: http://www.vidalpro.net
Ministero della salute, Italy. 2004 [cited; Available from: http://www.ministerosalute.it/index.jsp
Felleskatalogen. 2004 [cited; Available from: http://www.felleskatalogen.no
Base de datos del medicamento. 2004 [cited; Available from: http://pfarmals.portalfarma.com:8080/farma/
FASS.se för Förskrivare. [cited 2004-05-06]; Available from: http://www.fass.se
British National Formulary 2004
Conflict of interest statement
JAK and European health economics have received consulting fees from Merck. Dr. Shuvayu S. Sen is an employee of Merck & Co., Inc.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ström, O., Borgström, F., Sen, S.S. et al. Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries - an economic evaluation based on the fracture intervention trial. Osteoporos Int 18, 1047–1061 (2007). https://doi.org/10.1007/s00198-007-0349-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-007-0349-5